Literature DB >> 21689963

Neurotrophic factors for the treatment of Parkinson's disease.

Aideen M Sullivan1, André Toulouse.   

Abstract

Parkinson's disease (PD) is a common neurodegenerative disorder caused by the progressive degeneration of the nigrostriatal dopaminergic pathway. The resulting loss of dopamine neurotransmission is responsible for the symptoms of the disease. Available treatments are initially successful in treating PD symptoms; however, their long-term use is associated with complications and they cannot stop the neurodegeneration. Current research aims at developing new therapies to halt/reverse the neurodegenerative process, rather than treating symptoms. Neurotrophic factors are proteins critical for maintenance and protection of neurones in the developing and adult brain. Several neurotrophic factors have been investigated for their protective effects on dopaminergic neurones. Here we review some of the most promising factors and provide an update on their status in clinical trials.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21689963     DOI: 10.1016/j.cytogfr.2011.05.001

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  27 in total

1.  Canonical BMP-Smad signalling promotes neurite growth in rat midbrain dopaminergic neurons.

Authors:  Shane V Hegarty; Louise M Collins; Aisling M Gavin; Sarah L Roche; Sean L Wyatt; Aideen M Sullivan; Gerard W O'Keeffe
Journal:  Neuromolecular Med       Date:  2014-03-29       Impact factor: 3.843

2.  Class-IIa Histone Deacetylase Inhibition Promotes the Growth of Neural Processes and Protects Them Against Neurotoxic Insult.

Authors:  Louise M Collins; Luc J Adriaanse; Surabhi D Theratile; Shane V Hegarty; Aideen M Sullivan; Gerard W O'Keeffe
Journal:  Mol Neurobiol       Date:  2014-07-29       Impact factor: 5.590

Review 3.  Roles for the TGFβ superfamily in the development and survival of midbrain dopaminergic neurons.

Authors:  Shane V Hegarty; Aideen M Sullivan; Gerard W O'Keeffe
Journal:  Mol Neurobiol       Date:  2014-02-07       Impact factor: 5.590

4.  Fibroblast growth factor 1attenuates 6-hydroxydopamine-induced neurotoxicity: an in vitro and in vivo investigation in experimental models of parkinson's disease.

Authors:  Xiaojie Wei; Songbin He; Zhouguang Wang; Jiamin Wu; Jinjing Zhang; Yi Cheng; Jie Yang; Xinlong Xu; Zaifeng Chen; Junmin Ye; Li Chen; Li Lin; Jian Xiao
Journal:  Am J Transl Res       Date:  2014-11-22       Impact factor: 4.060

Review 5.  The role of TGF-β superfamily signaling in neurological disorders.

Authors:  Risa Kashima; Akiko Hata
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2018-01-01       Impact factor: 3.848

Review 6.  Hypoxia inducible factor-1 as a target for neurodegenerative diseases.

Authors:  Z Zhang; J Yan; Y Chang; S ShiDu Yan; H Shi
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

7.  Morphological Changes in a Severe Model of Parkinson's Disease and Its Suitability to Test the Therapeutic Effects of Microencapsulated Neurotrophic Factors.

Authors:  C Requejo; J A Ruiz-Ortega; H Bengoetxea; A García-Blanco; E Herrán; A Aristieta; M Igartua; J L Pedraz; L Ugedo; R M Hernández; J V Lafuente
Journal:  Mol Neurobiol       Date:  2016-11-14       Impact factor: 5.590

8.  Post 6-OHDA lesion exposure to stress affects neurotrophic factor expression and aggravates motor impairment.

Authors:  Phumzile Nomfundo Ngema; Musa Vuyisile Mabandla
Journal:  Metab Brain Dis       Date:  2017-03-20       Impact factor: 3.584

9.  Intranasal Administration of TAT-Conjugated Lipid Nanocarriers Loading GDNF for Parkinson's Disease.

Authors:  Sara Hernando; Enara Herran; Joana Figueiro-Silva; José Luis Pedraz; Manoli Igartua; Eva Carro; Rosa Maria Hernandez
Journal:  Mol Neurobiol       Date:  2018-01       Impact factor: 5.590

10.  Leuprolide acetate, a GnRH agonist, improves experimental autoimmune encephalomyelitis: a possible therapy for multiple sclerosis.

Authors:  Irene Guzmán-Soto; Eva Salinas; Irma Hernández-Jasso; J Luis Quintanar
Journal:  Neurochem Res       Date:  2012-07-26       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.